Immunology / Virology & Vaccines

#Funding #Immunology / Virology & Vaccines #mRNA

£4 million funding raised for rapid vaccine development platform  

Imophoron, the Bristol-based developer of a rapid-response vaccine platform, ADDomer, has secured £4 million in an oversubscribed fundraising round. Frederic Garzoni, CEO and Co-founder of Imophoron, said: “It has now been demonstrated how a pandemic cannot just threaten lives, but our society and economy as we know it. Imophoron is developing its ADDomer vaccine platform… Read More

#News

#Immunology / Virology & Vaccines #Malaria

WHO recommends GSK malaria vaccine for children at risk 

The World Health Organization (WHO) has recommended GlaxoSmithKline (GSK)’s RTS,S malaria vaccine to be given to children living in sub-Saharan Africa who are at risk of contracting Malaria.  RTS,S is the first and only malaria vaccine to have been shown in pivotal long-term clinical trials to significantly reduce… Read More

#News #Trending News

#AstraZeneca #Covid-19 #Drug development #Drug discovery #Events #Immunology / Virology & Vaccines

Race against the virus: Dame Sarah Gilbert discusses her virology journey 

In late December 2019, a cluster of unusual pneumonia cases – now known to be the first human cases of Covid-19 – were reported in Wuhan, China. Due to quick action from Dame Sarah Gilbert and her team, work on the response to the new virus began. Members of… Read More

#News

#Drug development #Drug discovery #Immunology / Virology & Vaccines #mRNA

AstraZeneca collaboration to develop RNA therapeutics  

AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialisastion of the self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London.  The strategic, long-term research collaboration aims to optimise and validate VaxEquity’s saRNA platform and apply it to advance novel therapeutic programmes. AstraZeneca will support VaxEquity with research and development funding and should… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines #Research

Why some people have stronger natural defences against SARS-COV-2 

A team of scientists at the MRC University of Glasgow Centre for Virus Research has revealed key research into the natural human antiviral defences against SARS-CoV-2, the virus that causes Covid-19.   In the study, the scientists reveal that some people have a version of a gene,… Read More

#News

#Awards #Covid-19 #Immunology / Virology & Vaccines

NIAID issues new awards to fund “pan-coronavirus” vaccines  

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded approximately $36.3 million to three academic institutions to conduct research to develop vaccines to protect against multiple types of coronaviruses and viral variants. The awards are intended to fuel vaccine… Read More

#News

#AstraZeneca #Covid-19 #Immunology / Virology & Vaccines #Moderna #Pfizer

Health Canada approves Moderna, Pfizer and AstraZeneca vaccines 

Health Canada has approved Moderna’s New Drug Submission (NDS-CV) for Spikevax (elasomeran mRNA vaccine), it has granted full approval (Notice of Compliance or NOC) for Pfizer’s Comirnaty, and it has approved the AstraZeneca vaccine, which will be named Vaxzevria.  “Health Canada’s approval of our Covid-19 vaccine is an important milestone as… Read More

#Covid-19 #News #Regulatory

#Cancer immunotherapy #Cancer research #Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Can Covid-19 vaccine technology be used for cancer vaccines?

Scientists from the University of Oxford and the Ludwig Institute for Cancer Research are building on the Oxford-AstraZeneca vaccine for SARS-CoV-2 to develop a vaccine to treat cancer.   Researchers have designed a two-dose therapeutic cancer vaccine using Oxford’s viral vector vaccine technology. When tested in mouse tumour models, the… Read More

#Cancer Research #Covid-19 #Editor's Choice #News

#Clinical trials #Collaboration #Covid-19 #Immunology / Virology & Vaccines #Pharmaceutical #Research

Early trial of first multivariant Covid-19 vaccine booster begins

A Phase I clinical trial of the world’s first multivariant Covid-19 vaccine has been launched by US pharmaceutical company Gritstone in collaboration with The University of Manchester UK and Manchester University NHS Foundation Trust.  Initially involving participants aged 60+, its creators say the drug, GRT-R910, can boost… Read More

#News

#Clinical trial #Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA #Research

Moderna: new clinical data on its Covid-19 vaccine 

New analysis suggests that the Moderna Covid-19 vaccine is highly effective against circulating variants of concern, including in a vaccine effectiveness study conducted in partnership with Kaiser Permanente Southern California (KPSC) and in a separate recent publication by the US Centers for Disease Control and Prevention (CDC).   Additionally, the company shared… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Podcast #Research

Putting virology back on the map: podcast 

This is the latest episode of the free DDW podcast, “Putting virology back on the map: the fight against Covid-19”. It covers two articles written for Volume 22, Issue 1 – Winter 2020/21 of the Drug Discovery World Magazine.   The first article is a case study titled… Read More

#News

#Clinical trials #HIV #Immunology / Virology & Vaccines #Johnson & Johnson

J&J HIV vaccine candidate does not protect women against HIV infection 

An investigational HIV vaccine tested in the “Imbokodo” clinical trial conducted in sub-Saharan Africa did not provide sufficient protection against HIV infection, according to a primary analysis of the study data. It posed no safety concerns. The Phase IIb proof-of-concept study, which began in November 2017, enrolled 2,637 women… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #Regulatory

Moderna submits CMA for its Covid-19 vaccine booster  

Moderna has submitted a conditional marketing approval (CMA) with the European Medicines Agency (EMA) for the evaluation of a booster dose of the Moderna Covid-19 vaccine (mRNA-1273) at the 50 µg dose level.  “We are pleased to submit for a conditional marketing approval with the EMA for our booster candidate at the 50… Read More

#Covid-19 #News #Trending News

Covid-19
#Covid-19 #FDA #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna submits initial data to FDA for Covid-19 vaccine booster 

Moderna has initiated its submission to the US Food and Drug Administration (FDA) for the evaluation of a booster dose of the Moderna Covid-19 vaccine (mRNA-1273) at the 50 µg dose level. The company expects to submit data to the European Medicines Agency (EMA) and other regulatory authorities around the world… Read More

#News